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Background: With the explosion of genomic data over the last decade, there has been a tremendous amount of
effort to understand the molecular basis of cancer using informatics approaches. However, this has proven to be
extremely difficult primarily because of the varied etiology and vast genetic heterogeneity of different cancers and
even within the same cancer. One particularly challenging problem is to predict prognostic outcome of the disease
for different patients.
Results: Here, we present ENCAPP, an elastic-net-based approach that combines the reference human protein
interactome network with gene expression data to accurately predict prognosis for different human cancers.
Our method identifies functional modules that are differentially expressed between patients with good and bad
prognosis and uses these to fit a regression model that can be used to predict prognosis for breast, colon, rectal,
and ovarian cancers. Using this model, ENCAPP can also identify prognostic biomarkers with a high degree of
confidence, which can be used to generate downstream mechanistic and therapeutic insights.
Conclusion: ENCAPP is a robust method that can accurately predict prognostic outcome and identify biomarkers
for different human cancers.
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The genetic complexity of cancer and its widely varying
etiology and outcome make it extremely difficult to treat.
It has been realized that rather than being a single disease,
different cancers have widely diverse molecular bases
[1,2]. There has been a tremendous amount of effort in
the literature to understand molecular signatures under-
lying cancer [1]. A significant number of these efforts have
been informatics-based approaches that try to leverage
genomic information such as expression alterations, muta-
tions in genomes, copy number changes and epigenetic
modifications to elucidate the mechanistic basis of cancer
[3]. Global collaborative research endeavors such as The
Cancer Genome Atlas (TCGA) [4] and the International
Cancer Genome Consortium (ICGC) [5] are trying to* Correspondence: haiyuan.yu@cornell.edu
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of cancers across many countries.
One of the key challenges has been to use genomic in-
formation to understand the basis for different outcomes
for the same cancer. However, this has been difficult be-
cause it is unclear as to which parameters contain the most
information regarding disease outcome. One of the first at-
tempts at predicting cancer prognosis using genome-scale
transcriptomic datasets was undertaken by van de Vijver
et al. [6]. Using microarrays, they obtained tissue-specific
gene-expression profiles for breast cancer patients. They
then clustered these expression profiles and correlated
them with prognostic outcome to identify a 70-gene ‘prog-
nosis profile’ for breast cancer. One of the key limitations
in using only expression datasets to predict cancer progno-
sis is the assumption of independence between genes in
hypothesis testing. The protein products encoded by these
genes are not independent but part of a complex interac-
tome network. The dependencies of this network have
been shown to be of great importance in understanding
the genetic and molecular bases of disease [7-11]. Chuang
et al. [12], Taylor et al. [13] and Wu and Stein [14] used ais is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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prognosis. Recently, Hofree et al. reported a network-based
stratification approach that can use somatic mutations to
predict cancer subtypes [15]. However, their method is
primarily designed to work with mutation data and is less
accurate for expression data [15]. Given the much wider
availability of expression datasets as compared to whole
genome or exome sequences, it is of paramount import-
ance to have a robust method that can use gene expression
to accurately predict prognosis across different types of
cancer. To this end, in this manuscript, we report
ENCAPP, an elastic-net-based cancer prognosis predic-
tion method. We use tissue-specific gene expression
data from patients along with the reference human pro-
tein interaction network to construct a regression model
that can predict disease outcome for breast, colon, rec-
tal, and ovarian cancers. Our approach outperforms
previous methods in terms of accuracy of prognosis pre-
diction. Moreover, ENCAPP can also accurately identify
genes that can serve as prognostic biomarkers for differ-
ent cancers.
Results and discussion
ENCAPP – a schematic
A reference high-quality human protein interactome was
constructed as described earlier [16]. Our interactome
comprises a total of 42,604 binary and co-complex inter-
actions among 9,985 proteins. We include both kinds of
interactions as they capture orthogonal layers of infor-
mation – binary interactions represent direct contacts
between two proteins, while co-complex associations
capture co-membership of a protein complex. This net-
work is clustered into different functional modules. We
overlay tissue-specific gene expression data from cancer
patients onto these functional modules to generate ‘ex-
pression modules’. We then identify ones that are differ-
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Figure 1 Schematic of ENCAPP. ENCAPP begins by overlaying tissue-spe
Modules that have significant differential co-expression between patients w
can predict prognostic outcome.prognosis (Figure 1). We use the expression modules that
show the maximum difference between the prognostic out-
come classes as decision boundaries to build a regression
model that can predict disease prognosis (Figure 1b). Our
regression approach attempts to estimate the conditional
probability of having good or bad prognosis given the pa-
tient’s expression modules.
Since the data is inherently high dimensional (i.e., the
number of expression modules is greater than the number
of patients), ordinary least squares regression cannot be
used and a regularization term is essential (see Methods).
While ridge regression (L2 regularization term) [17] uses all
input variables to fit the model, the least absolute shrinkage
and selection operator (LASSO, L1 regularization term)
[18] attempts to find the most optimal sparse fit. Ridge re-
gression can lead to inflated variance but has low bias,
while LASSO can have high bias but ensures low variance.
To optimize the bias-variance tradeoff, the elastic net
[19,20] has been proposed and is our choice of regression
model (see Methods).
Prognosis prediction using differentially expressed
functional modules
We first examined expression data from a cohort of breast
cancer patients [6]. Here, prognosis was defined as five-
year disease-free survival. Using five-fold cross validation,
we first measured prognosis prediction accuracy using
only expression values from all genes and found it to be a
suboptimal predictor (median AUC= 0.747, 95% CI for
AUC= 0.743-0.751 Figure 2A, see Methods). Since pro-
teins carry out their function by interacting with other
proteins, we then used only expression values from genes
whose corresponding proteins have at least one known
interaction to predict prognosis. This did not significantly
alter performance (median AUC = 0.745, Figure 2A).
Taylor et al. used hub groups as a measure of network
topology, however we choose modules for two reasons. . .
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Figure 2 Integrating gene-expression data with protein interactome networks. (A) Receiver operating characteristic (ROC) curves for
prognosis prediction using expression data alone. (B) Illustration of hub groups and networks modules. (C) ROC curves comparing the
performance of three module-detection algorithms – hierarchical clustering, affinity propagation clustering and ClusterOne.
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between the hub protein and its interactors, not those
between the interactors themselves. Thus, modules con-
tain more information. Second, in Taylor et al’s model,
each protein is assigned to one and only one hub group.
However, since network modules can be overlapping
[21,22], the same protein may be assigned to multiple
modules if it has multiple functions. Since numerous
proteins carry out biological functions in a pleiotropic
fashion, our approach captures such relationships while
hub groups do not.
To identify functional modules, we tried three separate
algorithms – hierarchical clustering [23], affinity propaga-
tion clustering [24] and ClusterOne [25]. We constructed
modules from all three algorithms using default parame-
ters (the module creation is independent of any expression
data). Using expression values from the van de Vijver
dataset, we used modules generated by all three algo-
rithms to construct expression modules and used them to
predict prognosis. We find that ClusterOne has the best
performance (Figure 2C; see Methods). One possible
reason for this is that the protein interactome network
is binary (1 corresponding to an interaction between
two proteins, while 0 corresponds to no interaction be-
tween the two proteins) and sparse. Thus, the number
of discrete values (equal to 1 + the graph diameter) the
graph distance used for hierarchical clustering can take
is limited. Affinity propagation clustering is more suited
to identifying hub-group-like topological structures as
hubs fit the definition of exemplars. On the other hand,
ClusterOne was designed to identify functional modules
that capture pleiotropic relationships. Thus, ClusterOne
was used for all further analyses.
We then explored the contribution of the three different
datasets – clinical covariates, gene expression and the pro-
tein network to predicting prognosis. Figure 3 presents a
flowchart of how these datasets are combined in ourENCAPP algorithm. We find that expression and network
in combination are the most informative (Figure 4A,
median AUC = 0.777; 95% CI for AUC = 0.773-0.780;
P < 10−3; Additional file 1: Table S1) and the addition of
clinical data only marginally improves the performance
(Figure 4a, AUC = 0.786; 95% CI for AUC = 0.783-0.789;
P < 10−3; Additional file 1: Table S1). ENCAPP also per-
forms much better than an approach that just uses
differential expression; we trained a generalized linear
model with differentially expressed genes selected using
the LIMMA package [26] and found that the median
AUC is 0.685, significantly lower than ENCAPP (P < 10−3).
These results confirm that using interaction dynamics, a
combination of gene expression data with the topological
structure of the network, is a key predictor of prognosis.
Our results also confirm that ENCAPP will work effi-
ciently even in the absence of clinical information, which
can be hard to collect and thus is often unavailable. Fur-
thermore, while we used ‘death’ as the outcome variable
for the prognosis prediction described above, we find that
it is robust to using other variables as outcome labels
(Additional file 2: Supplementary Notes).
To compare the performance of our method to previ-
ous attempts, we first compared our classification accur-
acy (i.e., the fraction of patients for which we were able
to accurately predict prognosis, see Methods) and AUC
to Taylor et al. (Figure 4B). Using expression data in con-
junction with the protein network, ENCAPP achieves a
median AUC of 0.777, significantly higher than the value
of 0.71 reported by Taylor et al (P < 10−3). We then com-
pared the performance of ENCAPP to that of Chuang
et al. At a fixed sensitivity of 90%, ENCAPP has a signifi-
cantly higher accuracy (75.1% vs 70.1%, P = 0.025). Finally,
we compared ENCAPP to the results reported by Wu and
Stein. Since they do not directly report ROC curves, we
adopted a slightly different approach for this comparison.
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For each gene k,
calculate:
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where Eki is the expression levels for gene k and patient i, s is the number of 
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- yi = prognostic outcome for the ith patient 
         (0 or 1 corresponding to good and bad prognosis respectively)
- xi = vector of features for the ith patient
- β’s = estimated regression coefficients
- λ = weight of the regularization term 
         (chosen to minimize mean square error)
- α is a number between 0 and 1 with α = 0 corresponding to ridge 
   regression alone and α = 1 corresponding to LASSO alone.
  (The best α is chosen using cross validation.)
where
Figure 3 Flowchart illustrating the different steps in ENCAPP.
The inputs to ENCAPP are RMA-normalized expression data and
modules from a reference human protein interactome network.
These are then combined into features that are input to an elastic-net
based regression model. The performance of the model is evaluated
using cross-validation.
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modules identified by them and attempted to predict
prognosis for the Wang dataset. We found that the me-
dian AUC is 0.510. We then used the same modules and
constructed the features that ENCAPP uses to train a
GLM. The median AUC goes up to 0.561, significantly
higher (P < 10−3) than the earlier median AUC.
We then sought to assess the changes that cause the
performance boost over previous methods. We used
ENCAPP on an experimentally verified subset of the
Ophid interactome used in the Taylor et al. study. We
obtained a median AUC of 0.750, which is significantly
higher (P = 0.040) than the AUC of 0.71 obtained by
them. This confirms that a large portion of the increase
in performance is solely due to the core methodology
underlying ENCAPP – our approach captures more in-
formation regarding the topology of the protein interac-
tome than Taylor et al because of the differences in hub
groups and modules outlined earlier. The rest of the in-
crease is due to a higher quality protein network used in
our study. The improvement in the protein network can
be attributed to two factors – a methodological enhance-
ment: we employ a series of stringent filtering steps [16]
to identify a set of high-quality interactions and an in-
crease in the available data. Thus, ENCAPP is a robust
and reliable method that combines expression data with
protein network modules to accurately predict cancer
prognosis; it works efficiently even in the absence of
clinical data.Robustness of ENCAPP
Is ENCAPP robust to changes of the response variable
or the incompleteness of the reference protein network?
To systematically test this, we first focused on how the
performance of ENCAPP changes when the response
variable is altered. For the van de Vijver dataset, he out-
come variable (survival) is right censored, i.e., if a patient
survives for > =5 years, she is considered to have good
prognosis, else bad prognosis. To test the robustness of
ENCAPP to the right censoring cutoff, we varied it from
3–14 years i.e, a patient is defined to have good progno-
sis if she survived for > =k years, where k varies from 3
to 14. We find that ENCAPP performs consistently well
for all values of k (Figure 4C), with the highest median
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Figure 4 (See legend on next page.)
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Figure 4 Predicting breast cancer prognosis using differentially expressed functional modules. (A) ROC curves for prognosis prediction
of patients in the breast cancer (2002) dataset using clinical data alone, expression data alone, expression data with the protein network and all
3 datasets together. (B) Comparison of the performance of ENCAPP with Taylor et (values shown are those obtained in the absence of clinical
information). (C) Boxplots showing performance of ENCAPP at different right censoring cutoffs k used for determining prognostic outcome: for
each boxplot, good prognosis is defined as survival for > =k years and bad as death within k years. (D) Boxplots showing performance of ENCAPP
at different right censoring cutoffs k used for determining prognostic outcome; here a different outcome definition is used: for each boxplot,
good prognosis is defined as no metastasis for > =k years and bad as metastasis within k years. (E) Boxplots showing performance of ENCAPP
using random networks that have 5%, 10%, 15% and 20% of the total edges in the original network randomly removed.
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wide range of cutoff values for right censoring.
To further validate the robustness of ENCAPP to alter-
nate definitions of prognosis, we modified the outcome
definition. We defined a patient to have a good prognosis,
if she does not have metastases for > = k years, where
k varies from 3 to 10. Here too, ENCAPP performs con-
sistently well (Figure 4D), with the highest median AUC
being 0.744 and the lowest median AUC being 0.652, con-
firming that it is also robust across prognosis definitions.
To address the robustness of ENCAPP to incomplete-
ness of the protein network, we generated sets of 50 ran-
dom networks for each of the following scenarios: 5%,
10%, 15% and 20% of the total edges randomly removed.
We then generated modules for all these random net-
works using the same ClusterOne parameters as the ori-
ginal network. We then re-calculated the performance of
ENCAPP on the van de Vijver dataset for each of these
networks with a certain fraction of the edges removed.
We find that ENCAPP still performs well, with median
AUCs of 0.744, 0.740, 0.743 and 0.742 at 5%, 10%, 15%
and 20% edge deletions respectively (Figure 4E), con-
firming that it highly robust to network incompleteness.Pan-cancer prognosis prediction
A major challenge of prognosis prediction algorithms is
to make them generically applicable to different human
cancers. To examine the applicability of ENCAPP for
other cancer types and sub-types, we first used it on a
dataset of lymph-node negative breast cancer patients
[27]. Although, van de Vijver et al. also examined breast
cancer patients, the consensus gene signature identified
was very different. Wang et al. stated that the results
vary so much “because of differences in patients, tech-
niques, and materials used” [27]. The van de Vijver data-
set included node-negative and node-positive patients
and women less than 53 years old. Moreover, prognosis
for the Wang dataset is defined as metastasis-free
survival. However, ENCAPP is still able to accurately
predict (median AUC = 0.690; 95% CI for AUC = 0.684-
0.695; P < 10−3; Additional file 1: Table S1) cancer prog-
nosis for these patients (Figure 5A), confirming that its
robustness across cancer sub-types.Another key goal of prognosis prediction algorithms is
to be applicable across data collected from different
cohorts of patients. To test whether ENCAPP can be
trained on a certain dataset and then used to predict
outcome for a completely different set of patients, we
used the Wang et al. dataset to train the model and then
predicted outcomes for the van de Vijver dataset using
it. While we originally analyzed the van de Vijver dataset
in terms of overall survival, clinical information on me-
tastasis was available. Since, the Wang et al. dataset uses
metastasis-free survival as the prognostic outcome, we
used this as the outcome for the cross-dataset prediction.
ENCAPP was accurate in predicting outcomes (median
AUC = 0.649; 95% CI for AUC = 0.649-0.650; P = 0.019;
Additional file 1: Table S1), showing that our approach is
highly robust and successful in incorporating major differ-
ences in clinical parameters (Figure 5B). Here too, we per-
form better than Chuang et al. who report a classification
accuracy of 55.8% at 90% sensitivity (for predictions on
the Wang dataset using the van de Vijver sub-network
markers). ENCAPP achieves a significantly higher classifi-
cation accuracy of 62.6% at 90% sensitivity (P = 0.009).
We then used ENCAPP to analyze other kinds of can-
cer – a colon cancer [28] and an ovarian cancer [29] ex-
pression dataset published by the TCGA. The ovarian
cancer dataset that we analyzed consisted of platinum-
resistant cancer patients, which occurs in approximately
25% of patients within 6 months of therapy. For each
dataset, we looked to see how well our method could
predict overall survival. ENCAPP was able to predict
prognostic outcome successfully for both colon and ovar-
ian cancer (median AUCs = 0.666 and 0.766 respectively;
95% CIs for AUC= 0.658-0.674 and 0.760-0.771 respect-
ively; P = 0.001 and 0.097 respectively; Additional file 1:
Table S1) confirming that it works robustly across differ-
ent cancers (Figures 5C, 5E).
Finally, we tried using ENCAPP to predict prognosis
across cancer types when they are related. We tried predict-
ing rectal cancer prognosis [28] having trained ENCAPP
using colon cancer data [28]. ENCAPP is very successful
(median AUC = 0.803; 95% CI for AUC = 0.782-0.823;
Figure 5D; P < 10−3; Additional file 1: Table S1) at pre-
dicting rectal cancer prognosis showing that ENCAPP is
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Figure 5 Prognosis prediction for different cancer types and subtypes. (A) ROC curves for prognosis prediction of patients in the breast
cancer (2005) dataset using expression data alone and expression data with the protein network. (B) ROC curves for prognosis prediction of
patients in the breast cancer (2002) dataset using data from the breast cancer (2005) dataset. (C) ROC curves for prognosis prediction of patients
in the colon cancer dataset using clinical data alone, expression data alone, expression data with the protein network and all 3 datasets together.
(D) ROC curves for prognosis prediction of patients in the rectal cancer dataset using data from the colon cancer dataset. (E) ROC curves for
prognosis prediction of patients in the ovarian cancer dataset using expression data alone and expression data with the protein network.
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Since our elastic net approach is a combination of
LASSO and ridge regression, the number of coefficients
with significant regression coefficients is relatively low
(Figure 6A, Additional file 3: Table S2; see Methods). The
modules whose corresponding coefficients are mathemat-
ically significant are termed ‘significant modules’. To test
the robustness of these ‘significant’ modules, we calculated
the Spearman rank correlation coefficient of these sig-
nificant modules across cross-validation runs and folds
(Additional file 4: Figure S1). We find that they are
highly stable: 99.1% have a rank correlation coefficient > =
0.98. To see if these modules are also biologically signifi-
cant, we examined the distribution of known cancer genes
in these modules (see Methods). We found that these
modules are significantly enriched for cancer genes
(Figure 6B; P < 0.01 for all 4 datasets). The fact that the
enrichment extends to the level of entire modules shows
that the differences in expression patterns extend to the
level of the modules themselves. This is conceptually
consistent with previous findings that gene sets rather
than genes themselves better explain dysregulation in can-
cer [30]. Thus differential co-expression of these modules
is a molecular determinant of different outcomes for
different patients.
We also compared the average degree of proteins in
these significant modules with that of cancer-associated
proteins (11.2) and all proteins in the network (8.2). The
average degree of proteins in significant modules is not,
in general, skewed towards the average degree of cancer-
associated proteins. For the van de Vijver and Wang
breast cancer datasets, the average degree of proteins in
significant modules are 12.0 and 10.5 respectively, simi-
lar to the average degree of cancer-associated proteins.
However, for the colon and ovarian cancer datasets, they
are 8.3 and 8.8 respectively, similar to the overall average
degree. These findings are also consistent with Figure 6B,
which shows that the enrichment of cancer genes in sig-
nificant modules for the 2002 and 2005 breast cancer
datasets is higher than the enrichment for the colon and
ovarian cancer datasets. This could be due to higher
noise for the colon and ovarian cancer datasets or due
to the list of cancer genes being incomplete with varying
degrees of incompleteness for different tissue types.
To examine whether the significant modules that we
find agree with what has been previously reported, wecompared the significant modules that we obtained for
the van de Vijver dataset with the significant modules that
Wu and Stein [14] obtained for the same dataset. 29/85
(34.1%) of the modules are overlapping. Thus, ENCAPP
does find a large number of signatures concordant with
what has been reported earlier, but it also finds a signifi-
cant number of potentially novel signatures. We then
compared the significant modules that we obtained for
the Wang dataset with the significant modules that Wu
and Stein obtained for the van de Vijver dataset. This is a
comparison both across methods and cancer sub-types.
25/268 (9.3%) of the modules are still overlapping, show-
ing that there are a number of stable signatures across
cancer sub-types. We also find that 3 significant modules
for the van de Vijver dataset contain 13 proteins of which
5 have been previously implicated in cancer (Figure 6C)
and 3 significant modules for the colon cancer dataset
contain 9/21 known cancer genes (Figure 6C). A number
of these genes are known to be good prognostic markers.
As a further validation, we examined prognostic bio-
markers detected by ENCAPP that were unknown at the
time of publication of the expression dataset, but have
since been clinically validated. Conceptually, these cor-
respond to novel biomarkers detected by ENCAPP. For
example, we detected NFKB2 and BCL3 in a significant
module for the breast cancer (2002) dataset (Figure 6C).
In 2005, it was shown that the NFκB complex, of which
NFKB2 is one of the subunits, can be used a well-known
prognostic marker for breast cancer [31]. More recently,
it has also been shown that suppression of the NFκB co-
factor BCL3 correlates with poor prognosis as it inhibits
apoptosis of mammary cells [32]. GATA2 was present in
a significant module for the colon cancer (published in
2011) dataset (Figure 6C). In 2013, GATA2 was shown
to be a useful prognostic marker for colorectal cancer –
patients with high expression levels of GATA2 are likely
to have worse disease-free survival outcomes than those
with lower expression levels of GATA2 [33]. These con-
firm that the significant modules identified by ENCAPP
contain numerous prognostic markers.
We also found a number of modules with proteins that
have not yet been validated as prognostic biomarkers but
are excellent candidates for hypothesis-driven follow-up
experiments. For example, one of the significant modules
for the breast cancer (2002) dataset contains CKS1B,
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Figure 6 Prognostic biomarker discovery using ENCAPP. (A) Distribution of regression coefficients for different human cancers. The red
shaded area corresponds to the top 10 percentile. Significant modules are defined as those with coefficients in the red shaded area. (B) Enrichment
of known cancer genes in the significant modules for the breast cancer (2002), breast cancer (2005), colon cancer and ovarian cancer datasets.
(C) Examples of significant modules for the breast cancer (2002) and colon cancer datasets. Known cancer genes are depicted in red. (D) Examples of
novel biomarker prediction for the breast cancer (2002) and colon cancer datasets.
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tion of PSMD9 (p27) [34]. A recent study shows that
PSMD9 expression is altered in breast cancer patients
irrespective of the BRCA mutation state [35]. Together,
these results suggest that this module and especially
CKS1B and SKP2 could be reliable prognostic markers
across breast cancer subtypes as altered expression of
these genes will lead to mis-regulation of PSMD9, whose
expression is altered in breast cancer patients with or
without mutations in BRCA1.
For the colon cancer dataset, one of the significant
modules contains FAM175B, BARD1, CSTF1, BRE, and
UIMC1 (Figure 6D). It is well known that BARD1 inter-
acts with BRCA1 to form a ubiquitin ligase complex
[36,37] and the interaction can be disrupted by breast
cancer mutations on BRCA1 [36,37]. A blood test based
on BARD1 has been proposed as a potential way to diag-
nose breast cancer [38]. FAM175B (ABRO1) and BRE
are two of the 4 subunits of the BRISC deubiquitinating
enzyme complex [39]. BRE has already been shown to be
a reliable prognostic marker for acute myeloid leukemia
[40,41]. In the context of these studies, our results suggest
that this module and especially FAM175B, BARD1 and
BRE can be potential prognostic markers for colon cancer
as altered expression of these genes can modify ubiquiti-
nation activity in the cell.
Conclusions
Here we have described ENCAPP, a robust prognosis pre-
dictor of different human cancers. Since ENCAPP uses
differentially expressed modules between patients with
good and bad prognosis to accurately predict disease out-
come, the decision boundaries used to make this predic-
tion correspond to functional changes in the cell. This is
potentially extremely useful in generating mechanistic
hypotheses regarding cancer causation and progression
that can then be experimentally tested. Conceptually, the
ENCAPP algorithm uses interaction dynamics, a combin-
ation of gene expression data with the topological struc-
ture of the network, to predict prognosis. Previous studies
have shown that interaction dynamics is also useful in un-
derstanding the organization and evolutionary modes of
biological networks [42,43]. Together, these suggest that
approaches using interaction dynamics may be successful
in elucidating the mechanistic basis of a wide range of
biological phenomena, by combining two discrete layers
of information – gene expression and protein networks.Another key feature of ENCAPP is its ability to identify
prognostic markers from the regression model itself.
While some previous methods show examples of prognos-
tically relevant genes identified by their method [13,15],
the key difference is that such detections are typically an-
ecdotal. On the other hand, we demonstrate that the sig-
nificant modules in ENCAPP are systematically enriched
for cancer genes. Thus, our model identifies biologically
relevant genes and uses these for determining prognostic
outcome. We also show that significant modules identi-
fied by ENCAPP contain known prognostic markers
and hypothesize that they may contain novel bio-
markers. Follow-up studies may want to validate these
putative prognostic markers. Since ENCAPP identifies
modules containing these genes, any positive results
emerging from such studies will directly tie in to a
pathway-level understanding of the mechanistic basis of
that specific cancer type.
One limitation of ENCAPP is that the accuracy of the
prognosis prediction is highly dependent on the quality
of the expression dataset, which is why the AUCs vary
across the different cancers. Future approaches may want
to combine gene expression and protein networks with
other data such as somatic mutations, epigenetic modifi-
cations and copy number alterations to make the overall
prediction accuracy less dependent on the quality of an in-
dividual dataset.
Methods
Expression data and the human protein interactome
network
Sample size, number of good and bad prognosis patients,
and breakdown by stage and grade for the different ex-
pression datasets used are available in Additional file 5:
Table S3. Expression data were RMA-normalized as
described in Additional file 2: Supplementary Notes.
High-quality binary and co-complex human protein in-
teractome networks were obtained from HINT [16]. The
final network used for this study was the union of the
binary and co-complex networks. It comprises 42,604
interactions between 9,985 proteins. All datasets used in
this study are obtained from papers that have already
been published and required no ethics approval.
Identifying functional modules using clustering
ClusterOne identifies overlapping functional modules based
on the topological properties of the protein interactome
Das et al. BMC Genomics  (2015) 16:263 Page 11 of 13network [25]. We did a sweep for the ‘s’ (size) and ‘d’
(minimum cluster density) parameters in ClusterOne [25].
The default parameters are s = 3 and d = 0.35. We exam-
ined the parameter space around these values. Since the
modules were identified independently of the expression
datasets, situations occasionally arose in which some
modules had missing gene expression values. In these
cases, a module was included only if at least 1/3 of the
genes in that module had corresponding expression
values. For each cancer type, we report the highest AUC
value obtained in the parameter sweep.
The elastic-net-based regression model
The elastic net [19] is a regularized regression model
that uses a linear combination of the L1 penalty term
from LASSO [18] and the L2 penalty term from ridge
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where, yi corresponds to the prognostic outcome for
the ith patient (0 or 1 corresponding to good and bad
prognosis). xi is a vector of a vector of features for the i
th
patient (please see below for a detailed description of xi).
The β’s are regression coefficients that we estimate. The
tuning parameter λ is the weight of the regularization term
and is chosen to minimize mean square error. The
regularization term Pα(β) is given by:








Here, α is a number between 0 and 1 with α = 0 corre-
sponding to ridge regression alone and α = 1 corre-
sponding to LASSO alone. We choose the best α using
cross validation.
For our first analysis (Figure 2a) that used only expres-
sion data, xi is a vector of dimension n containing expres-
sion values for n genes for the ith patient (The entire set of
expression values for d patients will be a matrix of size d x
n, where each row is the transpose of xi.). For ENCAPP, xi
is a vector of dimension 2n containing expression values
for n modules for the ith patient. Each functional module
m contributes 2 values – Gim and Bim to xi:
Pik ¼ Eik− < Ekg >
σkg
Qik ¼











Here, sm is the number of genes in module m. Eik corre-
sponds to the expression value of the kth gene for the ith
patient. < Ekg > and < Ekb > represent the average (mean)
expression values of the kth gene across all patients with
good and bad prognosis respectively. σkg and σkb represent
the standard deviation of the expression values of the kth
gene across all patients with good and bad prognosis re-
spectively. For all the cross-validations, < Ekg >, < Ekb >,
σkg and σkb are calculated using only the samples in the
training set. However, while using Gim and Bim as features
derived from every module generally gives the most
optimum performance, we noticed that in certain cases it
is possible to obtain a slight increase in performance by
not averaging over each module. There all Pik and Qik
values are used as input. While training the ENCAPP clas-
sifier, it is necessary to check which of the two approaches
performs better.
For the datasets where clinical information was also
available, we incorporated it using a logistic regression
model. A description of the available clinical data is
given in Additional file 6: Clinical information. Since the
clinical data is not high dimensional, elastic net regres-
sion is not a suitable choice for it. The final predicted
outcome was a weighted linear combination of the two
outputs – one predicted by the elastic-net-based model
(using expression and protein network data) and the
other predicted by the logistic regression model. Thus,
Y1 = f(X1) and Y2 = g(X2) and Y = k x Y1 + (1 - k) x Y2.
Here, X1 is the set of expression derived features, f the
function obtained from the elastic-net based classifier
and Y1 the corresponding outcome variable, X2 the set
of clinical features, f the function obtained from the
logistic-regression based classifier and Y2 the correspond-
ing outcome variable. Y is the final outcome obtained by a
linear combination of Y1 and Y2. An optimal value of k,
the relative weight parameter is obtained by grid search.
ENCAPP code and associated datasets are available
in the Supplementary information (Additional file 7:
ENCAPP_Code_Datasets).
Evaluating performance
The performance of our model is evaluated in a five-fold
cross validation framework (Additional file 2: Supplemen-
tary Notes). We split the patients into five subsets such
that four subsets are used for training and the fifth one is
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were used to determine the regression coefficients. These
coefficients were then used to predict outcomes for
patients in the test set. We repeated this procedure five
times so that each subset served as a test set. The pre-
dicted outcomes were compared to the actual outcomes
using a receiver operating characteristic (ROC) curve [44].
The area under the ROC curve (AUC) and classification
accuracy were used as measure of the quality of the pre-
diction [44]. The cross validation is process was repeated
50 times with a set of random seeds. For all comparisons,
each method was run with the same set of random seeds,
which ensured that the cross-validation dataset splits were
identical across methods. Thus, all observed differences
are solely due to one method being superior to the other
and not because of how the dataset was split into the 5
folds. P-values evaluating the significance of difference in
performance between different methods (two sets of AUC
values) were calculated using a Mann–Whitney U test.
Classification accuracy is measured at the optimum
point on the ROC curve. This is usually the point where
the slope of the curve (S) is given by:
S ¼ cðPjNÞ−cðN jNÞ
c N jPð Þ−c PjPð Þ 
N
P
Here, c(I|J) represents the cost of assigning class I to
class J. Here, P = true positives + false negatives and N =
true negatives + false positives are the total counts in the
positive and negative classes, respectively. For our calcula-
tions, we chose c(P|P) = c(N|N) = 0. And c(N|P) = c(P|N).
Substituting these values, we get,
S ¼ N
P
Enrichment of cancer genes in modules with significant
regression coefficients
To identify modules with significant regression coefficients,
we examined the distribution of coefficients and chose the
highest and lowest two percentile of coefficients as signifi-
cant (Figure 6A). We then examined the genes in these
modules and compared them to known cancer genes. A list
of known cancer genes was obtained from the Cancer
Gene Census [45]. This is a high-confidence list of manu-
ally curated cancer genes with orthogonal layers of evi-
dence, including but not limited to mutation information
from COSMIC [46]. The expected fraction of cancer genes




where Ci is the number of cancer genes and Ti the total
number of genes in modules in the ith expression dataset.The observed fraction of cancer genes in modules with




where Xi is the actual number of cancer genes and Ni the
total number of unique genes in these modules. Thus, the
enrichment of cancer genes in modules with significant
regression coefficients is given by:
En ¼ Of i
Ef i
P-values were calculated using a cumulative binomial
test.
Availability of supporting data
The datasets supporting the results of this article are in-
cluded within its additional files.
Additional files
Additional file 1: Table S1. Summary of AUCs and p values for the
different datasets.
Additional file 2: Supplementary Notes. Supplementary Notes.
Additional file 3: Table S2. Number of different modules identified by
each clustering method and list of significant modules identified by
ENCAPP for the breast cancer (2002), breast cancer (2005), colon cancer
and ovarian cancer datasets. All genes in a particular module are listed in
a single row. Each module is listed in a separate row.
Additional file 4: Figure S1. Distribution of Spearman rank correlation
coefficients between significant modules identified across cross validation
runs and folds.
Additional file 5: Table S3. Sample size, number of good and bad
prognosis patients, breakdown by stage and grade for the different
datasets.
Additional file 6: Clinical information. Description of the clinical
information used.
Additional file 7: ENCAPP_Code_Datasets. ENCAPP code and
associated datasets.
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